Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04705818
Recruitment Status : Not yet recruiting
First Posted : January 12, 2021
Last Update Posted : January 12, 2021
Sponsor:
Collaborators:
AstraZeneca
Epizyme, Inc.
Information provided by (Responsible Party):
Institut Bergonié

Brief Summary:
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Advanced Colorectal Carcinoma Advanced Soft-tissue Sarcoma Advanced Pancreatic Adenocarcinoma Adult Solid Tumor Drug: Durvalumab Drug: Tazemetostat Phase 2

Detailed Description:

4 independant, multicenter, prospective, signle-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of durvalumab when prescribed with tazemetostat, separately, in distinct cohorts of solid tumors:

  • cohort A: patients with pancreatic cancer
  • cohort B: patients with colorectal cancer not MSI-H or MMR-deficient
  • cohort C: patients with metastatic solid tumors with positive interferon gamma signature and/or tertiary lymphoid structure positive
  • cohort D: patients with soft-tissue sarcoma

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 173 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

4 independant single-arm, phase II trials, based on 2-stage Simon's optimal design:

  • cohort A: pancreatic cancer
  • cohort B: not MSI-H or MMR-deficient colorectal cancer
  • cohort C: metastatic solid tumor with positive interferon gamma signature and/or prensece of tertiary lymphoid structure
  • cohort D: soft-tissue sarcoma
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study
Estimated Study Start Date : April 2021
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A: pancreatic cancer
Patients with pancreatic cancer will be treated by durvalumab prescribed in association with tazemetostat
Drug: Durvalumab
Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Drug: Tazemetostat
Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Experimental: Cohort B: not MSI-H or MMR-deficient colorectal cancer
Patients with colorectal cancer will be treated bydurvalumab prescribed in association with tazemetostat
Drug: Durvalumab
Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Drug: Tazemetostat
Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Experimental: Cohort C: metastatic solid tumor
Patients with metastatic solid with positive interferon gamma signature and/or presence of tertiary lymphoid structurestumor will be treated bydurvalumab prescribed in association with tazemetostat
Drug: Durvalumab
Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Drug: Tazemetostat
Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Experimental: Cohort D: soft-tissue sarcoma
Patients with soft-tissue sarcoma will be treated by durvalumab prescribed in association with tazemetostat
Drug: Durvalumab
Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

Drug: Tazemetostat
Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).




Primary Outcome Measures :
  1. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A [ Time Frame: Within 6 months of treatment onset ]
    Antitumor activity will be assessed in terms of disease control rate, defined as complete response (CR), partial response (PR) and stable disease (SD) as per RECIST v1.1 criteria

  2. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort B [ Time Frame: Within 6 months of treatment onset ]
    Antitumor activity will be assessed in terms of disease control rate, defined as CR, PR and SD as per RECIST v1.1 criteria

  3. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort C [ Time Frame: Within 6 months of treatment onset ]
    Antitumor activity will be assessed in terms of objective response rate, defined as CR and PR as per RECIST v1.1 criteria

  4. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D [ Time Frame: 6 months ]
    Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria


Secondary Outcome Measures :
  1. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort D [ Time Frame: Within 6 months of treatment onset ]
    Antitumor activity will be assessed in terms of objective response rate, defined as CR and PR as per RECIST v1.1 criteria

  2. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A [ Time Frame: 6 months ]
    Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria

  3. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort B [ Time Frame: 6 months ]
    Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria

  4. Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort C [ Time Frame: 6 months ]
    Antitumor activity will be assessed in terms of 6-months progression-free rate, defined as CR, PR and SD as per RECIST v1.1 criteria

  5. 6-month objective response (OR) independently for each population [ Time Frame: 6 months ]
    Objective response is defined as the proportion of patients with complete response (CR) or partial response (PR) observed at 6 months, based on RECIST 1.1 criteria

  6. Best overall response, independently for each population [ Time Frame: Throughout the treatment period, an expected average of 6 months ]
    Best overall response is defined as the best response across all time points (RECIST 1.1). The best overall response is determinded once all the data for the patient is known (RECIST 1.1)

  7. 1-year progression-free survival, independently for each population [ Time Frame: 1 year ]
    Progression-free survival is defined as the delay between the start date of treatment and the date of progression (as per RECIST 1.1) or death (from any cause), whichever occurs first

  8. 1-year overall survival, independently for each population [ Time Frame: 1 year ]
    Overall survival is defined as the delay between the start date of treatment and the date of death (of any cause)

  9. Safety profile, independently for each population: Common Terminology Criteria for adverse events version 5 [ Time Frame: Throughout the treatment period, an expected average of 6 months ]
    Toxicity graded using the Common Terminology Criteria for Adverse Events vers 5

  10. Tumor immune cell levels [ Time Frame: before treatment onset, cycle 2 day 1 and cycle 3 day 1 (each cycle is 21 days) ]
    Levels of immune cells in tumors will be measured by immunohistochemistry

  11. Blood cytokines level [ Time Frame: before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days) ]
    Levels of cytokines in blood will be measured by ELISA

  12. Blood lymphocytes level [ Time Frame: before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days) ]
    Levels of lymphocytes in blood will be measured by flow cytometry

  13. Blood kynurenin level [ Time Frame: before treatment onset, cycle 2 day 1, cycle 3 day 1 and treatment discontinuation (each cycle is 21 days) ]
    Levels of kynurenin in blood will be measured by ELISA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histology: histologically confirmed solid tumors including pancreatic cancer (cohort A), non MSI-H or MMR-deficient colorectal cancer (cohort B), solid tumor with positive IFNG gene expression signature and/or tertiary lymphoid structure positive (cohort C), soft-tissue sarcomas (Cohort D). Other solid tumor types may be included through future amendment of the current version of the study protocol.

    Note: for cohort C, IFNG gene expression and/or presence of tertiary lymphoid structure will be centrally assessed. Cohort D, diagnosis must be confirmed and reviewed by the RRePS Network.as recommended by the French NCI (Inca).

  2. For cohort C, availability of archived FFPE tumor tissue sample for IFNG gene expression assessment and/or determination of the presence of tertiary lymphoid structure,
  3. Advanced disease defined as metastatic or unresectable locally advanced disease,
  4. Age ≥ 18 years,
  5. ECOG, Performance status ≤ 1,
  6. Measurable disease according to RECIST
  7. Life expectancy > 3 months,
  8. Participant must have advanced disease and must not be a candidate for other approved therapeutic regimen known to provide significant clinical benefit based on investigator judgment,
  9. Adequate hematological, renal, metabolic and hepatic functions
  10. No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
  11. At least three weeks since last chemotherapy, immunotherapy or any other pharmacological treatment and/or radiotherapy,
  12. Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment, excluding alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2
  13. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to inclusion.
  14. Both women and men must agree to use a highly effective method of contraception throughout the treatment period and for six months after discontinuation of treatment.
  15. Voluntary signed and dated written informed consents prior to any specific study procedure,
  16. Participants with a social security in compliance with the French law.

Exclusion Criteria:

  1. Previous treatment with durvalumab or tazemetostat,
  2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody,
  3. EGFR/ALK/ROS mutated NSCLC,
  4. Evidence of progressive or symptomatic central nervous system or leptomeningeal metastases,
  5. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  6. Previous enrolment in the present study,
  7. Participant unable to follow and comply with the study procedures because of any geographical, familial, social or psychological reasons,
  8. Known hypersensitivity to any involved study drug or of its formulation components,
  9. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
  10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment,
  11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan or interstitial lung disease with ongoing signs and symptoms at inclusion. History of radiation pneumonitis in the radiation field (fibrosis) is permitted,
  12. Has known active tuberculosis, hepatitis B or hepatitis C,
  13. Has a known history of Human Immunodeficiency Virus or known acquired immunodeficiency syndrome,
  14. Persistent proteinuria > 3.5 g/24 hours measured by urine protein-creatinine ratio from a random urine sample (≥ Grade 3, NCI-CTCAE v5),
  15. Major surgical procedure or significant traumatic injury within 28 days before inclusion,
  16. Non-healing wound, non-healing ulcer, or non-healing bone fracture,
  17. Participants with evidence or history of any bleeding diathesis, irrespective of severity,
  18. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to inclusion,
  19. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before inclusion (except for adequately treated catheter-related venous thrombosis occurring more than one month before inclusion),
  20. Ongoing infection > Grade 2 as per NCI CTCAE v5,
  21. Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management,
  22. Congestive heart failure ≥ New York Heart Association class 2,
  23. Unstable angina, new-onset angina (begun within the last 3 months),
  24. Myocardial infarction less than 6 months before inclusion,
  25. Uncontrolled cardiac arrhythmias,
  26. Pregnant or breast-feeding participants,
  27. Individuals deprived of liberty or placed under legal guardianship,
  28. Prior organ transplantation, including allogeneic stem cell transplantation,
  29. Known alcohol or drug abuse,
  30. Participants with any condition that impairs their ability to swallow and retain tablets,
  31. Other severe acute or chronic medical conditions including immune inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study,
  32. Participant with anti-Vitamine K oral anticoagulation therapy,
  33. Suspected or known intraabdominal fistula,
  34. Screening QTc interval > 480 msec is excluded,
  35. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04705818


Contacts
Layout table for location contacts
Contact: Antoine ITALIANO, MD,PhD (0)5.56.33.33.33 ext +33 a.italiano@bordeaux.unicancer.fr
Contact: Simone MATHOULIN-PELISSIER, MD,PhD s.mathoulin@bordeaux.unicancer.fr

Locations
Layout table for location information
France
Institut Bergonie
Bordeaux, France, 33076
Contact: Antoine ITALIANO, MD,PhD       a.italiano@bordeaux.unicancer.fr   
Principal Investigator: Antoine ITALIANO, MD,PhD         
Centre Leon Berard
Lyon, France, 69008
Contact: Philippe CASSIER, MD, PhD       philippe.cassier@lyon.unicancer.fr   
Institut Gustave Roussy
Villejuif, France, 94805
Contact: Christophe MASSARD, MD, PhD       christophe.massard@gustaveroussy.fr   
Sponsors and Collaborators
Institut Bergonié
AstraZeneca
Epizyme, Inc.
Layout table for additonal information
Responsible Party: Institut Bergonié
ClinicalTrials.gov Identifier: NCT04705818    
Other Study ID Numbers: IB2019-04
2019-003303-35 ( EudraCT Number )
First Posted: January 12, 2021    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Bergonié:
tertiary lymphoid structure
pancreatic cancer
soft-tissue sarcoma
immunotherapy
colorectal cancer
solid tumor
epigenetic
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Sarcoma
Colorectal Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents